London, United Kingdom
London, United Kingdom

AstraZeneca plc is a British multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales and has operations in over 100 countries.AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Sweden-based Astra AB and the UK-based Zeneca Group . It has made numerous corporate acquisitions, including of Cambridge Antibody Technology , MedImmune , and Spirogen .AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It had a market capitalisation of approximately £54.8 billion as of 1 August 2014, the sixth largest of any company with a primary listing on the London Stock Exchange. It has secondary listings on the New York Stock Exchange and the OMX exchange. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Astrazeneca and Cancer Research Technology Ltd | Date: 2017-04-05

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.


A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.


Patent
Astrazeneca | Date: 2017-01-25

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).


There is provided a process for the preparation of AZD5363, or a salt of AZD5363, comprising: (a) the reaction of 8-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-oxa-l,8- diazaspiro[4.5]decane-2,4-dione: or a salt thereof, with (S)-3-amino-3-(4-chlorophenyl)propan-1-ol, or a salt thereof, in the presence of base; and (b) either isolating AZD5363 or isolating AZD5363 as a salt. 8-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-oxa-1,8-diazaspiro[4.5]decane-2,4-dione is provided and is prepared by reacting 4-(alkyloxycarbonylamino)-1-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)piperidine-4-carboxylic acid, or a salt thereof, with a cyclising agent


The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5- c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.


Disclosed arecertain derivatives of benzoxazinone amidesof formula (I),or pharmaceutically acceptable salts thereof, (Formula (I)) that act as mineralocorticoid (MR) receptor modulatorsthat may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.


Patent
Astrazeneca | Date: 2017-03-22

The present invention discloses a dry powder inhaler (1) comprising a housing (10, 10) with: an air supply channel (100) fluidly connected with an air inlet opening (101, 102) of the housing (10, 10); a single circulation chamber (140) for deagglomeration of a powder formulation, wherein the circulation chamber (140) is fluidly connected and/or connectable with the air supply channel (100), and wherein the circulation chamber (140) is arranged downstream of the air supply channel (100); a mouthpiece (13) fluidly connected with the circulation chamber (140) via an outlet (143) of the circulation chamber (140), wherein the mouthpiece (13) is arranged downstream of the circulation chamber 140). The dry powder inhaler according to the present invention is characterised in that the dry powder inhaler (1) contains only one single dose of the powder formulation and in that during storage of the powder formulation the powder formulation is in direct contact with the housing (10, 10).


Patent
Astrazeneca | Date: 2017-06-07

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A-related pathologies such as Downs syndrome, - amyloid angiopathy such as, but not limited to, cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (mild cognitive impairment), Alzheimers disease, memory loss, attention deficit symptoms associated with Alzheimers disease, neurodegeneration associated with diseases such as Alzheimers disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinsons disease.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2017-01-04

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimers disease, fatty liver disease, short bowel syndrome, Parkinsons disease, cardiovascular disease, and other and disorders of the central nervous system.


The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancel- involving a gain of copy number of NRAS gene.

Loading Astrazeneca collaborators
Loading Astrazeneca collaborators